Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer
Copyright © 2021 Elsevier B.V. All rights reserved..
OBJECTIVES: Circulating tumor cells (CTCs) are associated with tumor spread, whereas cancer stem cells may be related to drug resistance. However, few studies have analyzed the levels of circulating cancer stem cells (CCSCs) and CTCs in patients with advanced non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: Treatment-naïve patients with EGFR-mutated NSCLC who received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy were recruited prospectively. The cell surface vimentin antibody was used for CTC detection and CD133 antibody for CCSC detection. CCSC and CTC levels were measured as cell count per 4 mL of blood, before treatment, after 2 and 12 weeks of treatment, and at disease progression. Data on clinical characteristics and outcomes were also collected.
RESULTS: At diagnosis (n = 29), the median CCSC and CTC levels were 0 (interquartile range, 0-2) and 3 (2-9), respectively. After 12 weeks, the CCSC and CTC levels were lower than those at diagnosis (CCSC: 0 (0-0), p = 0.14; CTC: 1 (0-4), p = 0.048). At disease progression, the median CCSC and CTC levels were 0 (0-1) and 1 (0-2), respectively. Patients with higher CCSC and CTC levels at diagnosis had a numerically shorter progression-free survival.
CONCLUSION: In patients with EGFR-mutated NSCLC, CCSC and CTC levels became lower after 12 weeks of EGFR-TKI therapy and remained low at disease progression. High pre-treatment CCSC and CTC levels may be associated with a trend towards poor treatment outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
Lung cancer (Amsterdam, Netherlands) - 156(2021) vom: 15. Juni, Seite 50-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hsu, Chia-Lin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.06.2021 Date Revised 24.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lungcan.2021.04.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324480636 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324480636 | ||
| 003 | DE-627 | ||
| 005 | 20231225190419.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2021.04.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1081.xml |
| 035 | |a (DE-627)NLM324480636 | ||
| 035 | |a (NLM)33894494 | ||
| 035 | |a (PII)S0169-5002(21)00155-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hsu, Chia-Lin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.06.2021 | ||
| 500 | |a Date Revised 24.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVES: Circulating tumor cells (CTCs) are associated with tumor spread, whereas cancer stem cells may be related to drug resistance. However, few studies have analyzed the levels of circulating cancer stem cells (CCSCs) and CTCs in patients with advanced non-small cell lung cancer (NSCLC) | ||
| 520 | |a MATERIALS AND METHODS: Treatment-naïve patients with EGFR-mutated NSCLC who received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy were recruited prospectively. The cell surface vimentin antibody was used for CTC detection and CD133 antibody for CCSC detection. CCSC and CTC levels were measured as cell count per 4 mL of blood, before treatment, after 2 and 12 weeks of treatment, and at disease progression. Data on clinical characteristics and outcomes were also collected | ||
| 520 | |a RESULTS: At diagnosis (n = 29), the median CCSC and CTC levels were 0 (interquartile range, 0-2) and 3 (2-9), respectively. After 12 weeks, the CCSC and CTC levels were lower than those at diagnosis (CCSC: 0 (0-0), p = 0.14; CTC: 1 (0-4), p = 0.048). At disease progression, the median CCSC and CTC levels were 0 (0-1) and 1 (0-2), respectively. Patients with higher CCSC and CTC levels at diagnosis had a numerically shorter progression-free survival | ||
| 520 | |a CONCLUSION: In patients with EGFR-mutated NSCLC, CCSC and CTC levels became lower after 12 weeks of EGFR-TKI therapy and remained low at disease progression. High pre-treatment CCSC and CTC levels may be associated with a trend towards poor treatment outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cancer stem cells | |
| 650 | 4 | |a Circulating tumor cell | |
| 650 | 4 | |a Epidermal growth factor receptor tyrosine kinase inhibitor | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a Progression free survival | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Vimentin |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Tsai, Tzu-Hsiu |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chun-Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ching-Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Wei-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Chao-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Sheng-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Kuan-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Shih, Jin-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Pan-Chyr |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer (Amsterdam, Netherlands) |d 1994 |g 156(2021) vom: 15. Juni, Seite 50-58 |w (DE-627)NLM074973657 |x 1872-8332 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2021 |g day:15 |g month:06 |g pages:50-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lungcan.2021.04.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2021 |b 15 |c 06 |h 50-58 | ||